Jay A. Grobler

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

37h-index7.1kcitations83works1.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(45), HIV Research and Treatment(40), Biochemical and Molecular Research(15), HIV/AIDS Research and Interventions(12), SARS-CoV-2 and COVID-19 Research(12)

Publications83 total

Weekly Oral Prophylaxis With MK-8527 Protects Rhesus Macaques From Intrarectal Challenge With Simian–Human Immunodeficiency Virus
The Journal of Infectious Diseases·2025Open Access
MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing
PLoS Biology·2025· 1 citedOpen Access
Effectiveness of islatravir post‐exposure prophylaxis after intravenous challenge with simian immunodeficiency virus in rhesus macaques
Journal of the International AIDS Society·2025Open Access
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study
Clinical Trials·2025· 1 citedOpen Access
No antagonism or cross-resistance and a high barrier to the emergence of resistance <i>in vitro</i> for the combination of islatravir and lenacapavir
Antimicrobial Agents and Chemotherapy·2024· 7 citedOpen Access
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Infectious Diseases and Therapy·2024· 1 citedOpen Access
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)
Microbiology Spectrum·2024· 2 citedOpen Access
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Infectious Diseases and Therapy·2023· 8 citedOpen Access
Discovery of arylsulfonamides as a novel class of allosteric integrase inhibitors with antiviral activity
Bioorganic & Medicinal Chemistry Letters·2023· 2 cited
Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1
Science Translational Medicine·2023· 24 cited
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
Infection·2023· 33 citedOpen Access
153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro
Open Forum Infectious Diseases·2022· 3 citedOpen Access
Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Antimicrobial Agents and Chemotherapy·2022· 40 citedOpen Access
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance
Antimicrobial Agents and Chemotherapy·2022· 23 citedOpen Access
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19
NEJM Evidence·2021· 124 cited
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
NEJM Evidence·2021· 96 cited
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
New England Journal of Medicine·2021· 1.8k citedOpen Access
543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies
Open Forum Infectious Diseases·2021· 10 citedOpen Access
511. Treatment with Molnupiravir in the MOVe-In and MOVe-Out Clinical Trials Results in an Increase in Transition Mutations Across the SARS-CoV-2 Genome
Open Forum Infectious Diseases·2021· 1 citedOpen Access
Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial
Nature Medicine·2021· 65 cited
page 1 of 5Next →

Frequent Co-authors

Daria J. Hazuda(22), Michael D. Miller(9), Ming‐Tain Lai(8), Marc Witmer(6), Peter J. Felock(5), Amy S. Espeseth(5), John Wai(5), Osvaldo Flores(5), Min Xu(5), Michelle Brown(4), Julie Strizki(4), Amanda Paschke(4), Joan R. Butterton(4), Carisa De Anda(4), Kara A. Stillmock(4), Melissa S. Egbertson(4), David B. Olsen(4), Eric Markel(4), Meizhen Feng(4), Ernest Asante‐Appiah(4)